Şunu aradınız:: hydrogénophénylmalonate (Fransızca - İngilizce)

hydrogénophénylmalonate de phényle
phenyl hydrogen phenylmalonate

hydrogénophénylmalonate d'indane-5-yle
indan-5-yl hydrogen phenylmalonate

dénomination des marchandises 7-chloro-2-oxoheptanoate d'éthyle, sous la forme d'une solution dans le toluène; 7-chloro-2-oxoheptanoate d'éthyle; dl-mandélate d'éthyle; n-{2-[(acétylthio)méthyl]-3-(o-tolyl)-1-oxopropyl}-l-méthionate d'éthyle; hydrogénophénylmalonate d'indane-5-yle; concentré intermédiaire issu d'un milieu de fermentation d'escherichia coli génétiquement modifié, contenant un facteur de stimulation de colonies granulocytes macrophages, destiné à la fabrication de médicaments de la position no 30.02; concentré intermédiaire issu d'un milieu de fermentation d'escherichia coli génétiquement modifié, contenant de l'interféron humain alpha-2b, destiné à la fabrication de médicaments de la position no 30.02; concentrés intermédiaires issus d'un milieu de fermentation de micromonospora inyoensis, destinés à la fabrication des antibiotiques sisomicine (dci) et nétilmicine (dci); concentrés intermédiaires issus d'un milieu de fermentation de micromonospora purpurea, destinés à la fabrication des antibiotiques sulfate de gentamicine (dcim) et isépamicine (dci); 2,3-dihydro-1h-pyrrolizine-1-carboxylate d'isopropyle; isopropyl[2-(pipérazine-1-yl)-3-pyridyl]amine; l-lysyl-l-leucyl-l-leucyl-l-leucyl-l-leucyl-l-lysyl-l-leucyl-l-leucyl-lleucyl-l-leucyl-l-lysyl-l-leucyl-l-leucyl-l-leucyl-l-leucyl-l-lysyl-lleucyl-l-leucyl-l-leucyl-l-leucyl-l-lysine; bis[(2,3-dihydro-1,5-diméthyl-3-oxo-2-phényl-1h-pyrazole-4-yl) méthylamino]méthanesulfonate de magnésium; méso-n-benzyl-3-nitrocyclopropane-1,2-dicarboximide; (2r,3s)-2,3-époxy-3-(4-méthoxyphényl)propionate de méthyle; (2r,3s)-3-benzamido-2-hydroxy-3-phénylpropionate de méthyle; (4-nitrophényl)-l-alaninate de méthyle; 1h-1,2,4-triazole-3-carboxylate de méthyle; 2-(3-nitrobenzylidène)-3-oxobutyrate de méthyle; 7-[(3rs)-3-hydroxy-5-oxocyclopent-1-ényl]heptanoate de méthyle; di(acétate) de n,n'-dibenzyléthylènediammonium; 7,7-dioxyde de n-(5,6-dihydro-6-méthyl-2-sulfamoyl-4h-thiéno[2,3b]thiopyranne-4-yl)acétamide; n-(9-acétyl-6-oxo-6,9-dihydro-1h-purine-2-yl)acétamide; n-(benzyloxycarbonyl)-l-valine; n-(benzyloxycarbonyl)-s-phényl-l-cystéine; n-(tert-butyl)-3-méthylpyridine-2-carboxamide; acide n-[(r)-2-({(r)-2-[(2-adamantyloxycarbonyl)amino]-3-(1h-indole-3yl)-2-méthyl-1-oxopropyl}amino)-1-phényléthyl]succinamique--1désoxy-1-méthylamino-d-glucitol (1:1); n-[2-isopropylthiazole-4-ylméthyl(méthyl)carbamoyl]-l-valine; acide n-{5-[(1,4-dihydro-2-méthyl-4-oxoquinazoline-6-ylméthyl) méthylamino]-2-thénoyl}-l-glutamique; omega-conotoxine m viia; (2r,5r,6s)-6-[(r)-1-hydroxyéthyl]-3,7-dioxo-1-azabicyclo[3.2.0]heptane2-carboxylate de p-nitrobenzyle; bis{3-[1-(3,4-diméthoxybenzyl)-6,7-diméthoxy-1,2,3,4-tétrahydro-2isoquinolyl]propionate} de pentaméthylène--acide oxalique (1:2); chloroformiate de pentyle; 1-(1-hydroxyéthyl)-5-méthoxy-2-oxo-1,2,5,6,7,8,8a,8b-octahydroazéto[2,1-a]isoindole-4-carboxylate de potassium; purine-6(1h)-one; quinuclidine-3-ol;
description of goods 3,20-dione; adenosine; alpha,4-dibromo-2-fluorotoluene; alpha-acetyl-gamma-butyrolactone; ammonium (z)-2-methoxyimino-2-(2-furyl)acetate; benzhydryl 3-hydroxy-7-(phenylacetamido)cepham-4-carboxylate; benzyl (1r,2s)-3-chloro-2-hydroxy-1-(phenylthiomethyl)propylcarbamate; benzyl (1s,2s)-3-[(3s,4as,8as)-3-tert-butylcarbamoylperhydro-2isoquinolyl]-2-hydroxy-1-(phenylthiomethyl)propylcarbamate; benzyl l-alaninate--p-toluenesulfonic acid (1:1); benzyl(2-pyridyl)amine; cytosine; danaparoid sodium; dibenzoyl-l-tartaric acid; dimethyl{2-[5-(1h-1,2,4-triazol-1-ylmethyl)indol-3-yl]ethyl}amine; ethyl (1-cyanocyclohexyl)acetate; ethyl (7-chloro-2,4-dioxo-1,2,3,4-tetrahydroquinazolin-1-yl)acetate; ethyl (s)-3-(4-aminophenyl)-2-phthalimidopropionate hydrochloride; ethyl (s)-3-{4-[bis(2-chloroethyl)amino]phenyl}-2-phthalimidopropionate hydrochloride; ethyl (z)-2-(2-aminothiazol-4-yl)-2-(methoxyimino)acetate; ethyl [3-(cyanomethyl)-4-oxo-3,4-dihydrophthalazin-1-yl]acetate; ethyl 1-cyclopropyl-6,7-difluoro-4-oxo-1,4-dihydroquinoline-3carboxylate; ethyl 1h-tetrazole-5-carboxylate, sodium salt; ethyl 2-(hydroxyimino)-2-[2-(tritylamino)thiazol-4-yl]acetate hydrochloride; ethyl 7-chloro-2-oxoheptanoate, in the form of a solution in toluene; ethyl 7-chloro-2-oxoheptanoate; ethyl dl-mandelate; ethyl n-{2-[(acetylthio)methyl]-3-(o-tolyl)-1-oxopropyl}-l-methionate; indan-5-yl hydrogen phenylmalonate; intermediate concentrate obtained from a genetically-modified escherichia coli fermentation medium, containing human granulocytemacrophage colony-stimulating factor, used for the manufacture of medicaments of heading no. 30.02; intermediate concentrate obtained from a genetically-modified escherichia coli fermentation medium, containing human interferon alpha-2b, used for the manufacture of medicaments of heading no. 30.02; intermediate concentrates obtained from a micromonospora inyoensis fermentation medium used for the manufacture of the antibiotics sisomicin (inn) and netilmicin (inn); intermediate concentrates obtained from a micromonospora purpurea fermentation medium used for the manufacture of the antibiotics gentamicin sulfate (innm) and isepamicin (inn); isopropyl 2,3-dihydro-1h-pyrrolizine-1-carboxylate; isopropyl[2-(piperazin-1-yl)-3-pyridyl]amine; l-lysyl-l-leucyl-l-leucyl-l-leucyl-l-leucyl-l-lysyl-l-leucyl-l-leucyl-lleucyl-l-leucyl-l-lysyl-l-leucyl-l-leucyl-l-leucyl-l-leucyl-l-lysyl-lleucyl-l-leucyl-l-leucyl-l-leucyl-l-lysine; magnesium bis[(2,3-dihydro-1,5-dimethyl-3-oxo-2-phenyl-1h-pyrazol-4yl)methylamino]methanesulfonate; meso-n-benzyl-3-nitrocyclopropane-1,2-dicarboximide; methyl (2r,3s)-2,3-epoxy-3-(4-methoxyphenyl)propionate;